CN1283637C - 具有抗肿瘤活性的取代n－苄基吲哚－3－基乙醛酸衍生物 - Google Patents

具有抗肿瘤活性的取代n－苄基吲哚－3－基乙醛酸衍生物 Download PDF

Info

Publication number
CN1283637C
CN1283637C CNB008182094A CN00818209A CN1283637C CN 1283637 C CN1283637 C CN 1283637C CN B008182094 A CNB008182094 A CN B008182094A CN 00818209 A CN00818209 A CN 00818209A CN 1283637 C CN1283637 C CN 1283637C
Authority
CN
China
Prior art keywords
acid
cooh
alkyl
salt
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008182094A
Other languages
English (en)
Chinese (zh)
Other versions
CN1420880A (zh
Inventor
E·甘瑟尔
P·艾米格
D·雷彻特
G·里鲍特
B·尼科尔
G·巴施尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Publication of CN1420880A publication Critical patent/CN1420880A/zh
Application granted granted Critical
Publication of CN1283637C publication Critical patent/CN1283637C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
CNB008182094A 1999-12-23 2000-12-19 具有抗肿瘤活性的取代n－苄基吲哚－3－基乙醛酸衍生物 Expired - Fee Related CN1283637C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19962300.7 1999-12-23
DE19962300A DE19962300A1 (de) 1999-12-23 1999-12-23 Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung

Publications (2)

Publication Number Publication Date
CN1420880A CN1420880A (zh) 2003-05-28
CN1283637C true CN1283637C (zh) 2006-11-08

Family

ID=7934006

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008182094A Expired - Fee Related CN1283637C (zh) 1999-12-23 2000-12-19 具有抗肿瘤活性的取代n－苄基吲哚－3－基乙醛酸衍生物

Country Status (31)

Country Link
US (1) US6432987B2 (https=)
EP (1) EP1240157B1 (https=)
JP (1) JP2003519137A (https=)
KR (1) KR100747425B1 (https=)
CN (1) CN1283637C (https=)
AR (1) AR027098A1 (https=)
AT (1) ATE259364T1 (https=)
AU (1) AU772745B2 (https=)
BG (1) BG106924A (https=)
BR (1) BR0016712A (https=)
CA (1) CA2395259A1 (https=)
CO (1) CO5251472A1 (https=)
CZ (1) CZ20022094A3 (https=)
DE (2) DE19962300A1 (https=)
DK (1) DK1240157T3 (https=)
ES (1) ES2215768T3 (https=)
HK (1) HK1054038B (https=)
HU (1) HUP0203716A3 (https=)
IL (1) IL150235A0 (https=)
MX (1) MXPA02006229A (https=)
NO (1) NO324750B1 (https=)
NZ (2) NZ533731A (https=)
PL (1) PL195014B1 (https=)
PT (1) PT1240157E (https=)
RU (1) RU2266280C2 (https=)
SK (1) SK8752002A3 (https=)
TR (1) TR200400601T4 (https=)
TW (1) TWI284128B (https=)
UA (1) UA75060C2 (https=)
WO (1) WO2001047913A2 (https=)
ZA (1) ZA200204896B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
DE10318609A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318611A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
BRPI0410998A (pt) * 2003-06-05 2006-07-04 Zentaris Gmbh derivados de indol com efeito de indução de apoptose
US7211588B2 (en) * 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
JP5385605B2 (ja) * 2005-03-11 2014-01-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
US8884020B2 (en) * 2006-08-07 2014-11-11 Ironwood Pharmaceuticals, Inc. Indole compounds
EP2091532A1 (en) * 2006-11-28 2009-08-26 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1028812A (en) * 1962-08-28 1966-05-11 Ici Ltd Indole derivatives
CA2135160A1 (en) * 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Indole derivative
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
DK0746544T3 (da) * 1994-02-22 1999-06-07 Merrell Pharma Inc Indolderivater til behandling af østrogenafhængige neoplasmer og sygdomme
BR9501404A (pt) * 1994-04-01 1996-03-05 Lilly Co Eli 1H-indol-3 glioxilamida e formulação farmacèutica
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
AU6229298A (en) * 1997-02-20 1998-09-09 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
US5972988A (en) * 1997-03-26 1999-10-26 Eli Lilly And Company Method for treatment of chronic bronchitis using indole compounds
WO1998047507A1 (en) * 1997-04-24 1998-10-29 Shionogi & Co., Ltd. Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
TW455581B (en) * 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
EP1007056A1 (en) * 1997-09-26 2000-06-14 Eli Lilly And Company Method for the treatment of cystic fibrosis
AU1200799A (en) * 1997-10-27 1999-05-17 Eli Lilly And Company Isopropyl ester prodrugs of indole spla2 inhibitors
ES2241178T3 (es) * 1997-10-27 2005-10-16 Eli Lilly And Company Profarmacos de ester de morlino-n-etilo de inhibidores indolicos de spla 2.
CA2309135A1 (en) * 1997-10-27 1999-05-06 Michael Lyle Denney N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors
WO1999024033A1 (en) * 1997-11-12 1999-05-20 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
AU1405899A (en) * 1997-11-14 1999-06-07 Eli Lilly And Company Treatment for alzheimer's disease
EE200000488A (et) * 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaasensüümide inhibiitorid ja farmatseutilised kompositsioonid
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DZ2770A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
DE19818964A1 (de) * 1998-04-28 1999-11-04 Dresden Arzneimittel Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
TR200003130T2 (tr) * 1998-04-28 2001-01-22 Arzneimittelwerk Dresden Gmbh Yeni hidroksiindoller, bunların fosfodiesteraz 4 inhibitörleri olarak kullanımları ve hazırlanmaları için işlemler
BR9910095A (pt) * 1998-05-01 2000-12-26 Lilly Co Eli Compostos inibidores de spla2 para tratamento de doença
ID27812A (id) * 1998-05-01 2001-04-26 Lilly Co Eli ESTER PENGHAMBAT sPLA2
AU4834200A (en) * 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action

Also Published As

Publication number Publication date
US6432987B2 (en) 2002-08-13
PT1240157E (pt) 2004-06-30
EP1240157B1 (de) 2004-02-11
JP2003519137A (ja) 2003-06-17
ATE259364T1 (de) 2004-02-15
TR200400601T4 (tr) 2004-04-21
IL150235A0 (en) 2002-12-01
WO2001047913A3 (de) 2002-04-25
NO20023039L (no) 2002-08-09
DE19962300A1 (de) 2001-06-28
BR0016712A (pt) 2002-09-03
WO2001047913A2 (de) 2001-07-05
NZ519977A (en) 2004-08-27
PL355684A1 (en) 2004-05-17
KR100747425B1 (ko) 2007-08-09
NO20023039D0 (no) 2002-06-21
NZ533731A (en) 2005-03-24
RU2002120462A (ru) 2004-01-10
CA2395259A1 (en) 2001-07-05
DK1240157T3 (da) 2004-06-14
CN1420880A (zh) 2003-05-28
MXPA02006229A (es) 2003-01-28
SK8752002A3 (en) 2003-01-09
HUP0203716A2 (hu) 2003-03-28
KR20020063245A (ko) 2002-08-01
RU2266280C2 (ru) 2005-12-20
ZA200204896B (en) 2002-12-20
EP1240157A2 (de) 2002-09-18
BG106924A (bg) 2003-04-30
US20010014690A1 (en) 2001-08-16
ES2215768T3 (es) 2004-10-16
NO324750B1 (no) 2007-12-03
AU2011901A (en) 2001-07-09
HUP0203716A3 (en) 2004-05-28
UA75060C2 (en) 2006-03-15
AU772745B2 (en) 2004-05-06
HK1054038B (zh) 2007-04-13
DE50005284D1 (de) 2004-03-18
CO5251472A1 (es) 2003-02-28
PL195014B1 (pl) 2007-07-31
TWI284128B (en) 2007-07-21
HK1054038A1 (en) 2003-11-14
AR027098A1 (es) 2003-03-12
CZ20022094A3 (cs) 2002-10-16

Similar Documents

Publication Publication Date Title
CN1283637C (zh) 具有抗肿瘤活性的取代n－苄基吲哚－3－基乙醛酸衍生物
JP6049630B2 (ja) Ａｉｄｓを処置する為に有用な化合物
CN1148183C (zh) 具有抗肿瘤作用的吲哚基-3-乙醛酸衍生物
CN1227542A (zh) 具有抗哮喘、抗过敏和免疫抑制/免疫调节作用的n－取代的吲哚－3－乙醛酰胺类化合物
TWI433672B (zh) 吲唑化合物
CN1258279A (zh) 作为细胞增殖抑制剂的氰基胍
CN112521371A (zh) 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
CN1067885A (zh) 2-氨基嘧啶-4-甲酰胺衍生物及其制法和医疗应用
CN1183778A (zh) 喹啉羧酸衍生物
CN1816543B (zh) 具有细胞凋亡诱导效应的吲哚衍生物
JP2921760B2 (ja) フタルイミド誘導体及びそれら誘導体を含んでなる医薬
CN115677704B (zh) 含有7H-吡咯并[2,3-d]嘧啶结构的组蛋白去乙酰化酶6抑制剂及制备方法和应用
CN1067987C (zh) 取代的吲哚衍生物
CA3191013A1 (en) An improved highly efficient process for the prepration of nintedanib and pharmaceutically acceptable salt thereof
HK1036408B (en) Indolyl-3-glyoxylic acid derivatives with antitumoral activity
MXPA00009646A (en) Indolyl-3-glyoxylic acid derivatives with antitumoral activity
CZ20003483A3 (cs) Deriváty indolyl-3-glyoxylové kyseliny s protinádorovým účinkem

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee